Third Rock Ventures Reduces Stake in Tango Therapeutics Below 5% Threshold
TNGX has more than doubled off its 52-week low of $1.03.
Summary
Third Rock Ventures, a significant institutional investor, has reduced its ownership in Tango Therapeutics to 4.74% through open market sales totaling approximately $18.84 million, crossing the 5% reporting threshold.
Key Events · Ownership and Investor Activity · TNGX
-
Significant Stake Reduction
Third Rock Ventures decreased its ownership from above 5% to 4.74% of Tango Therapeutics' common stock.
-
Substantial Open Market Sales
The reduction was executed through multiple open market dispositions between January 21, 2026, and February 6, 2026, totaling approximately 1.5 million shares for about $18.84 million.
-
Below Reporting Threshold
The institutional investor's stake has now fallen below the 5% threshold, which typically reduces future detailed reporting obligations.
Analysis · TNGX · Life Sciences
This Schedule 13D/A filing indicates that Third Rock Ventures, a major institutional investor, has significantly reduced its stake in Tango Therapeutics. The sales, totaling approximately $18.84 million, represent a substantial capital outflow and have brought their ownership below the 5% threshold, which typically triggers a change in reporting requirements. While institutional investors often rebalance portfolios, a reduction of this magnitude by a long-term holder can be interpreted as a decrease in conviction or a strategic reallocation of capital. Investors should monitor future filings for further changes in institutional ownership.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNGX was trading at $12.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.03 to $13.46. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.